Organigram Holdings Inc. (TSE:OGI - Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$1.77 and last traded at C$1.78, with a volume of 212154 shares trading hands. The stock had previously closed at C$1.83.
Wall Street Analyst Weigh In
Several brokerages have recently commented on OGI. Canaccord Genuity Group dropped their price target on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating on the stock in a research note on Monday, December 9th. ATB Capital decreased their price objective on shares of Organigram from C$5.25 to C$3.50 in a report on Tuesday, December 17th.
View Our Latest Analysis on Organigram
Organigram Stock Down 4.6 %
The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07. The business has a 50-day simple moving average of C$2.17 and a 200-day simple moving average of C$2.29. The stock has a market cap of C$206.32 million, a P/E ratio of -3.53, a PEG ratio of 0.42 and a beta of 1.13.
About Organigram
(
Get Free Report)
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Featured Articles
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.